ARCHIVES

With $1.1 Billion At Stake, Cancer Groups Mull Comparative Effectiveness Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 20 | May 22, 2009

Download PDF Visit The Full Archive

Related Articles

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

Advocacy Groups Consider Pros And Cons Of Forming Co-Pay Foundations.

April 28, 2006

Hybridoma Cell Lines Available from NCI

September 3, 1982

Promising Areas Of Research Listed By NCAB Subcommittee

February 12, 1982

In Brief: House Passes appropriations Bill; Senate Markup in Late Summer; Kirschstein Acting NIH Director

July 9, 1993

In Brief: Senate Committee Refuses to Cut NCI 1982 Funds; Linus Pauling to Speak At conference On Vitamins

November 13, 1981